Destiny Pharma’s microbiome project for Clostridioides difficile infection

Neil Clark, CEO of Destiny Pharma (AIM:DEST) spoke with Amy Brown at Evaluate Vantage about Destiny’s microbiome project for Clostridioides difficile infection which is in development and differentiates them from other players.  “We are coming in as a first-line therapy, and looking at lower pricing” than those going for the high-recurrence end of the market, he says.

Read full Evaluate Vantage article here

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH